T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EGRX
2801
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $83K | ﹤0.01% |
+15,748
| New | +$86.4K |
|
|
AHT
2802
Ashford Hospitality Trust
AHT
$20.1M
| $81K | ﹤0.01% |
5,850
+2,880
| +97% | +$44.4K |
|
2803
CarParts.com
PRTS
$48.7M
| $81K | ﹤0.01% |
4,961
+435
| +10% | +$10.9K |
|
2804
Rayonier Advanced Materials
RYAM
$577M
| $81K | ﹤0.01% |
16,931
+1,552
| +10% | +$6.61K |
|
2805
Entravision Communication
EVC
$861M
| $80K | ﹤0.01% |
48,470
+1,733
| +4% | +$5.72K |
|
|
AMRN
2806
Amarin Corp
AMRN
$298M
| $79K | ﹤0.01% |
4,387
| – | – |
|
2807
Bionano Genomics
BNGO
$13.5M
| $79K | ﹤0.01% |
1,173
+648
| +123% | +$48.4K |
|
2808
Bit Digital
BTBT
$527M
| $78K | ﹤0.01% |
27,168
+4,280
| +19% | +$11.8K |
|
|
IAUX
2809
i-80 Gold Corp
IAUX
$1.44B
| $78K | ﹤0.01% |
58,013
+12,737
| +28% | +$18.4K |
|
2810
Workhorse Group
WKHS
$34.4M
| $78K | ﹤0.01% |
110
+50
| +83% | +$43.1K |
|
2811
W&T Offshore
WTI
$543M
| $78K | ﹤0.01% |
29,409
+6,187
| +27% | +$17.7K |
|
|
GTHX
2812
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $77K | ﹤0.01% |
17,755
| – | – |
|
2813
Citizens
CIA
$201M
| $75K | ﹤0.01% |
34,900
| – | – |
|
2814
US Global Investors
GROW
$38.8M
| $75K | ﹤0.01% |
26,700
| – | – |
|
|
BGFV
2815
DELISTED
Big 5 Sporting Goods
BGFV
| $74K | ﹤0.01% |
20,909
-1,468
| -7% | -$7.06K |
|
2816
Coherus Oncology
CHRS
$176M
| $74K | ﹤0.01% |
30,851
+7,608
| +33% | +$18.7K |
|
|
KLRS
2817
Kalaris Therapeutics
KLRS
$94.7M
| $74K | ﹤0.01% |
4,260
+2,387
| +127% | +$38.9K |
|
2818
Codexis
CDXS
$177M
| $73K | ﹤0.01% |
20,794
+2,314
| +13% | +$7.29K |
|
2819
PMV Pharmaceuticals
PMVP
$65.1M
| $73K | ﹤0.01% |
42,802
+17,858
| +72% | +$33.4K |
|
2820
Outdoor Holding Co
POWW
$261M
| $73K | ﹤0.01% |
26,303
+5,171
| +24% | +$12.1K |
|
|
BLUE
2821
DELISTED
bluebird bio
BLUE
| $71K | ﹤0.01% |
2,736
+1,456
| +114% | +$37.3K |
|
2822
PLAYSTUDIOS Inc
MYPS
$67.3M
| $70K | ﹤0.01% |
25,116
+4,546
| +22% | +$10.5K |
|
2823
PDS Biotechnology
PDSB
$13.5M
| $70K | ﹤0.01% |
17,539
+1,786
| +11% | +$9.2K |
|
2824
Intellicheck
IDN
$73.5M
| $68K | ﹤0.01% |
19,500
| – | – |
|
2825
Amplify Energy
AMPY
$209M
| $67K | ﹤0.01% |
+10,071
| New | +$61.2K |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.